Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

J Med Chem 2019 02 20;62(3):1180-1202. Epub 2018 Dec 20.

Global Health R&D , GlaxoSmithKline , Calle Severo Ochoa, 2 , 28760 Tres Cantos , Madrid Spain.

The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated. Current standard of care for VL suffers from multiple issues and there is a limited pipeline of new candidate drugs. As such, there is a clear unmet medical need to identify new treatments. This paper describes the optimization of a phenotypic hit against Leishmania donovani, the major causative organism of VL. The key challenges were to balance solubility and metabolic stability while maintaining potency. Herein, strategies to address these shortcomings and enhance efficacy are discussed, culminating in the discovery of preclinical development candidate GSK3186899/DDD853651 (1) for VL.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b01218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407917PMC
February 2019
30 Reads

Publication Analysis

Top Keywords

development candidate
8
preclinical development
8
visceral leishmaniasis
8
clear unmet
4
drugs clear
4
maintaining potency
4
stability maintaining
4
medical identify
4
unmet medical
4
potency strategies
4
pipeline candidate
4
multiple issues
4
organism key
4
suffers multiple
4
issues limited
4
strategies address
4
identify treatments
4
limited pipeline
4
candidate drugs
4
metabolic stability
4

Altmetric Statistics

Similar Publications